Work

Cholinergic deficiency and inflammation in cognitive dysfunction

Year: 2008
Type: other
Abstract: extensive clinical research one has to conclude that the effect of cholinesterase inhibitors in AD is truly limited.If strict responder criteria are used, and putative placebo effects are accounted for, CEI therapy is successful in only 5 to 15% of AD patients, whereas patients who are treated with CEIs frequently encounter serious side-effects (Cochrane reviews) [6][7][8] .With the advancing scientific insights in disease mechanisms it is now known that AD is a highly heterogeneous entity.Currently, beta-amyloïd and presenilins are considered by many to be the most important factors in the process that leads to widespread degeneration of cortical networks underlying dementia in AD 9 .It is widely acknowledged that loss of cholinergic transmission alone cannot account for the whole clinicopathological picture of AD.Notwithstanding these new insights in the pathogenesis, CEIs are the only available drugs that are licensed.Across numerous clinical trials there is a consistent effect of CEIs, not only in patients with AD but also with other forms of dementia such as DLB and Parkinson's disease dementia (PDD).Factors that might a priori predict a response to cholinesterase inhibitors have not yet been identified 10 .In the first part of this thesis we discuss the issue of cholinergic deficiency and response to CEI therapy in different ways.In Chapter 2 it is hypothesized that a cholinergic deficiency syndrome can be delineated that may occur in various forms of dementia and that can serve as indication for therapy with CEIs.Based on literature this syndrome is suggested to resemble the symptoms seen in delirium.In Chapter 3 a prospective study is described that investigates in detail the clinical characteristics of responders to therapy with the CEI rivastigmine.These features are thought to constitute the hallmarks of the cholinergic deficiency syndrome.Chapter 4 describes the role of electroencephalography in identifying responders to CEI-therapy in addition to clinical measures.A putative clinical correlate of the cholinergic deficiency syndrome is discussed in Chapter 5 where neuroleptic sensitivity as a manifestation of cholinergic deficiency leads to a false diagnosis of Creutzfeldt-Jakob disease.Rational and cost-effective use of CEIs has also been the subject of the guidance of the United Kingdom's National Institute of Clinical Excellence and health (NICE).This guideline caused a major uproar in societal and political sense in the UK in 2007.Chapter 6 is a reaction to these events.This paper advocates the concept of the cholinergic deficiency syndrome as indication for therapy with CEIs and urges pharmaceutical companies to release trial data in order to gain more insight into the clinical characteristics of responders to CEI-treatment. Introduction 13 InflammationNot long after the intense interest in the role of specific neurotransmitter systems subsided, a new area which focused the attention in the field of dementia research developed.Availability of specific antibodies in the 1980's stimulated increasing insight in the immune system and inflammatory processes.It became clear that inflammatory processes in the brain affect cognitive functioning.This was based on the discovery of three disease mechanisms.First, neurodegenerative diseases are accompanied by an inflammatory response.Pathological studies showed that microglia, the macrophages of the brain, become activated and release cytokines.Whether these inflammatory mediators have a primarily causative, a facilitating or counter-regulatory function remains controversial 11 .It is remarkable in this context that the pathological hallmarks of neurodegenerative disease such as amyloid-beta plaques in AD, tau in FTD or alpha-synucleïnepathology in DLB, do not completely explain the clinical symptoms 12 .Second, it became widely acknowledged that aging itself is accompanied by a low-grade inflammatory state expressed by alterations in concentrations of circulating proand anti-inflammatory cytokines in serum 11,13 .This is associated with age-related diseases such as atherosclerosis, diabetes mellitus and AD.In the brain similar immunological changes occur as a result of aging as expressed by the presence of activated microglia 14 .This could be elicited by other pathological changes in the brain as mentioned before.Alternatively it has been proposed that microglia activation in elderly is a result of aging of the microglia themselves.It is proposed that inflammation in combination with neuro-endocrinological changes and sarcopenia, conceptualized as frailty, put an older person at risk for adverse outcomes 15 .This concept, however, is still in need of support by robust evidence from observational or experimental studies.Important to the understanding of the role of inflammatory markers and cognitive function was the elaborate research on infectious processes.Inflammation in peripheral tissue is accompanied by a systemic reaction of release of cytokines in the blood.As a result of the infection the body creates a new homeostasis accompanied by fever, reduced appetite, and neurobehavioral changes, collectively known as sickness behavior 16 .It is now well established that raised levels of circulating cytokines induce these behavioral changes through interaction with the brain, especially via interleukin-1.Several pathways have been proposed that may play a role in this cross-talk between the peripheral immune system and the brain, but the activation of microglia in the brain parenchyma seems to be pivotal 17,18 .
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W1776415265
Cites: 195
Cited by: 1
Related to: 9